Gene therapeutic treatment of pancreatic cancer based on injection of pcDNA3.1/CCK plasmid with xenogeneic homologous cholecystokinin.
OBJECTIVE
To study the therapeutic effect of recombinant plasmid pcDNA3.1/CCK containing porcine gene of cholecystokinin (CCK).


METHODS
The confirmed fragments of porcine CCK cDNA were cloned into the pcDNA3.1 vector. Recombinant plasmid pcDNA3.1/CCK was injected into the muscles of Syrian golden hamsters. Before gene transfer, orthotopic tumor model and liver metastasis model of hamster pancreatic cancer have been established by injection of 1 x 10(6) PGHAM-1 cells into the pancreas and spleen of golden hamsters. Then the CCK expression in vivo and the tumor inhibiting effect were analyzed.


RESULTS
Our data revealed that recombinant plasmid pcDNA3.1/CCK had long-term expression in hamsters and induced generation of specific antibody. Antibody level correlated with the number of inoculations. Compared to the control, significant reduction in tumor volume, decrease in number of liver metastasis and a remarkable enhancement of survival rate were detected.


CONCLUSIONS
Intramuscular injection of recombinant plasmid pcDNA3.1/CCK has significant antitumor and antimetastatic effect in vivo.
Lu
Y
Y
Department of General Surgery, First Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
Bai
J G
JG
Wang
H H
HH
D000818:Animals; D000906:Antibodies / Q000097:blood; D017209:Apoptosis; D049109:Cell Proliferation; D002766:Cholecystokinin / Q000235:genetics* / Q000276:immunology; D006224:Cricetinae; D005260:Female; D015870:Gene Expression; D015316:Genetic Therapy; D007267:Injections; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000556:secondary; D018482:Muscle, Skeletal / Q000737:chemistry; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000628:therapy*; D010957:Plasmids / Q000008:administration & dosage; D012333:RNA, Messenger / Q000032:analysis; D013552:Swine; D023041:Xenograft Model Antitumor Assays
D000906:Antibodies; D012333:RNA, Messenger; D002766:Cholecystokinin